In particular, the binding energies of Perospirone and Ganetespib to IGF1R were lower than that of the native ligand (PubChem CID: 137349240), which implies that these two compounds have a greater affinity for IGF1R, suggesting that Perospirone and Ganetespib can be used for combination therapy of HNSCC. The gene discussed is IGF1R; the disease is head and neck squamous cell carcinoma.